BACKGROUND: Previous studies have reported higher rates of advanced Gleason score among black versus white men with prostate cancer in the United States. However, few studies have examined if elevated Gleason scores among black men vary by country of birth. We examined differences in prostate cancer disease severity among US black men born in the United States and in Jamaica, West Africa and other sub-Saharan Africa countries. METHODS: Our study included 19 798 US-born, 267 Jamaican-born, and 246 West African-born black men diagnosed with prostate cancer during [2004][2005][2006][2007][2008][2009] in the 18 Surveillance Epidemiology and End Results population-based cancer registries. We evaluated the association of advanced Gleason score (7-10), as well as PSA levels and stage by country of origin adjusting for age, and countylevel income. RESULTS: Among men with known Gleason score, the percentage of advanced Gleason score (scores 7-10) was 61.11% in Jamaican-born, 60.99% in West African-born and 58.26% in US-born black men (P-value ¼ 0.49). In a multivariable analysis among black men, there were no differences in advanced Gleason score (scores 7-10 versus 2-6) by country of origin. Mean PSA level (range 12.8-13.1 ng ml À 1 ) did not vary among black men (P-value ¼ 0.94) in unadjusted and adjusted results. CONCLUSIONS: Similar Gleason score among US-born, African and Caribbean-born black men were observed. Future more detailed studies are needed to elucidate if these similarities are a result of similar early detection practices or shared risk factors.
INTRODUCTION
Black men in the United States have one of the highest incidence and mortality rates worldwide. 1 Several studies have noted higher Gleason score, a strong prognostic factor of prostate cancer treatment and survival, 2 in black men compared with white men in the United States. 3 However, few studies have examined the variation in Gleason score among black men in the United States according to their country of birth. In addition to addressing potential variations in disease severity among black men, comparing Gleason scores between US-born black men and sub-Saharan African men immigrating to the United States may provide additional insights on the role of biological factors due to shared ancestry. 4 The Surveillance Epidemiology End Results (SEER) data set of the National Cancer Institute is unique in that it routinely collects data on case demographics, primary tumor site, tumor morphology and stage at diagnosis. 5 The SEER program also collects data on a place of birth for a substantial portion of the cases. In the present study, we examine Gleason score among black men born in the United States and immigrants from West African and other sub-Saharan countries in the SEER database. Men from Jamaica were also analyzed as they were the largest group of black men outside of the United States in the SEER database. In addition to Gleason score, we also examine PSA levels as this is a potential measure for disease severity.
MATERIALS AND METHODS
Data from the SEER population-based cancer registry covering B28% of the US population were used in this study. 5 Since 2004, SEER has collected data for PSA lab values and Gleason score as site-specific factors in the Collaborative Staging System. 6 Thus, our study focuses on malignant prostate cancer cases diagnosed between 2004 and 2009 (n ¼ 317 440). Cases diagnosed before 18 years of age (n ¼ 23), missing county-level household income (n ¼ 136) or race/ethnicity (n ¼ 11 400), and whose race/ ethnicity was not black or white (n ¼ 17 001) were excluded. Cases whose birth place was not in countries of interest (n ¼ 15 247) were also excluded. Since there were fewer than 100 black cases in all other sub-Saharan Africa combined (n ¼ 82), they were also removed from the analyses. There were 84 835 (44.93%) cases with the place of birth recorded and used for analysis.
The primary outcome was advanced Gleason score (defined as Gleason score 7-10) and the secondary outcome was PSA level. At the time of this study, SEER recorded Gleason scores based on the largest specimen (from needle biopsy or radical prostatectomy), but did not specify which process was used. 6 PSA was based on the highest lab value before diagnosis or treatment. 6 A sensitivity analysis redefining advanced Gleason score as a score of 8-10 was completed to determine whether results changed with this higher cut point. We also evaluated primary and secondary patterns for Gleason score 7, as there is known variability in outcomes for 3 þ 4 patterns versus 4 þ 3 patterns in sensitivity analyses.
84 were born in not otherwise specified West African countries. Age at diagnosis and median county-level household income according to the 2000 census were used as covariates. SEER summary stage at diagnosis (local/regional, distant and missing) was included as a covariate in models. Receipt of radical prostatectomy was also adjusted for because of previously noted discrepancies between needle biopsy and surgical Gleason score. 8, 9 Two-tailed w 2 -tests (a ¼ 0.05) were used to determine variations in Gleason score and other categorical variables by place of birth. The KruskalWallis test was used to examine variations in PSA level. 10 Multivariable logistic regression was employed to analyze advanced Gleason score among men with non-missing Gleason score. Supplemental analyses restricted to men receiving radical prostatectomy were also conducted because of the aforementioned potential variations in needle biopsy and prostatectomy Gleason score. In addition, we performed supplemental analyses restricted to men diagnosed with local and regional disease. PSA level was not normally distributed (Kolmogrov-Smirnov P-value o0.01), so log-PSA was analyzed as a continuous variable using multivariable linear regression. Cases missing the outcome of interest were excluded from that particular analysis; 88.65% (n ¼ 18 005) and 80.38% (n ¼ 16 326) cases had complete data and were included in the respective analyses of Gleason score and PSA level. All statistical analysis was performed using SAS software (version 9.2; Statistical Institute, Cary, NC, USA).
RESULTS
The mean age at diagnosis among black men varied by birth place and ranged from 61.2 years in West African-born blacks to 65.1 years among US-born blacks (P-value o0.01) ( Table 1) . Gleason score (including those with unknown Gleason scores) did not vary by place of birth among black cases (P-value ¼ 0.75) ( Table 1) . Among men with known Gleason score, the percentage of advanced Gleason score (scores 7-10) was 61.11% in Jamaicanborn, 60.99% in West African-born and 58.26% in US-born black men; these differences were not statistically significant (P-value ¼ 0.49) ( Figure 1 ). As a point of comparison, 55.53% of US-born whites had advanced Gleason scores, which was significantly different than that of black men in our study (Pvalueo0.01). Among cases with Gleason score 7, the distribution of 3 þ 4 pattern was more common than 4 þ 3 pattern and was similar for US-born (4919/7013, 70%), Jamaica-born (73/101, 72%), and West Africa-born black men (72/97, 74%) (P-value ¼ 0.82). Among men with known Gleason score, the percentage with Gleason score X8 was 16.92%, 17.71% and 18.38% for Jamaican, West African and US-born black men, respectively (P-value ¼ 0.92).
In a multivariable model among black cases adjusting for age and income, there were no differences in advanced Gleason score by country of origin (Table 2) . Additional adjustment for stage did not significantly alter the significance of the results (Table 2) . Similarly, adjustment for radical prostatectomy did not alter the significance of the results and point estimates approximated those when only age and income were accounted for. Using a higher cut point to define advanced Gleason score (scores of 8-10) did not alter results in models restricted to black men where Jamaicanborn men (odds ratio (OR) ¼ 1.01; 95% confidence interval (CI) 0.72-1.42), West African-born men (OR ¼ 1.17; 95% CI 0.77-1.79) had similar age and income adjusted odds of advanced Gleason score as US-born black men. In a multivariable model, including US-born whites as a referent where age and income were adjusted for, US-born blacks (OR ¼ 1.18; 95% CI 1.14-1.22), Jamaican (OR ¼ 1.34; 95% CI 1.03-1.74) and West African (OR ¼ 1.40; 95% CI 1.07-1.84) also had a higher odds of advanced Gleason score (scores of 7-10).
Models restricted to men diagnosed with regional or local disease (n ¼ 16 727) were similar to the main analyses containing all patients. When only age and income were adjusted for, the odds of advanced Gleason score was similar for Jamaican (OR ¼ 0.98; 95% CI 0.67-1.45) and West African-born (OR ¼ 1.26; 95% CI 0.86-1.84) black men compared with US-born black men (Table 3) . When receipt of radical prostatectomy was adjusted for, Comparison includes US-born, West African-born, and Jamaican-born black men.
Prostate cancer disease severity SA Fedewa and A Jemal the odds of advanced Gleason score was similar among US-born, Jamaican-born and West African-born black men (Table 3 ). In models restricted to men receiving radical prostatectomy (n ¼ 4716), the adjusted OR for Jamaican-born (OR ¼ , while 23.5 and 19.3% of West African and Jamaicanborn black men had PSA values X10 ng ml À 1 (P-value ¼ 0.43). In multivariable linear regression among black cases, the estimated average log-PSA level was 0.97 or 9.33 ng ml À 1 for those in the referent category (Table 4 ). There were no differences in PSA level by place of birth in multivariable models. Models restricted to local-regional stage disease were similar (data not shown).
DISCUSSION
In our study of SEER prostate cancer cases, the proportion of cases diagnosed with advanced Gleason score was similar among US-born, African and Caribbean-born black men. Immigrants in our study also had comparable Gleason scores as those reported in their respective native regions, [11] [12] [13] [14] with few exceptions. 15, 16 Jamaicanborn men in our study (61%) had remarkably similar proportions of advanced Gleason score as previously reported in men residing in Jamaica (62.1%) 13 and Jamaican-born men in the United States (60%). 17 Proportions of advanced Gleason score among West African-born men in our study (61%) were relatively similar to those reported in the West African countries of Burkina Faso (54.7%), 12 Ghana (56%) 14 and Nigeria (58%). 11 However, two studies in Nigeria 15, 16 reported substantially lower rate (20-40%) of advanced Gleason relative to other studies in the region. 11, 12, 14 Whether these discrepancies reflect smaller sampler sample size and/or underestimate of disease severity in these two studies is not known.
In general, the comparable Gleason score among foreign born and US-born black men in our study, and indigenous sub-Saharan men in previous studies may likely reflect the importance of biologic factors in the development of advanced Gleason score tumors. 18, 19 Prostate cancer disease severity SA Fedewa and A Jemal heterogeneous and dynamic group, they have some shared genetic roots due to trans-Atlantic slave practices in the 1800s. 20 Furthermore, the generally similar rate of advanced Gleason scores among men of African descent in our population, with those in native populations where PSA testing and other modalities of early detection (digital rectal exam) 11 are not routinely practiced, may support the hypothesis that cancers with advanced Gleason score may have a shorter lead time among black men. 21 The similar Gleason scores observed among black men in our study also may reflect similar screening and early detection rates. The role of PSA screening on advanced Gleason score prevention has not been fully elucidated due to potential length time bias. 22 Some studies suggest Gleason scores grow quickly from the time they arise and have a shorter length time, 21 while others suggest that Gleason scores have a longer natural history and progress from low to high grade could be amenable to intervention. 22 The role of screening on PSA levels is more clear as PSA is thought to progress over time and may be mitigated through early detection. Our observed similar PSA levels among black men according to place of birth in our study may be explained by similar screening rates among black men in our study. Though overall PSA screening rates are generally lower for foreign born men (which includes Asians, whites, blacks and Hispanics), 23 a previous study found comparable PSA screening rates between foreign-born black men (41%) and US-born black men (40%) over the age of 50. 24 Compared with studies among black men living in Africa, black men in our study had much lower PSA levels and early stage disease, [12] [13] [14] 16 which reflects the aforementioned lack of PSA testing and early detection in these countries.
Our descriptive study should be interpreted with care given its limitations. A substantial proportion of black men (n ¼ 25 274, 55%) were excluded from our analyses because of missing place of birth. The proportion of advanced Gleason score among black men with known place of birth was slightly higher (54%) than black men with unknown place of birth (58%) (P-value o0.01). Contributing factors for these differences are unknown. Nevertheless, inclusion of black men with missing place of birth did not alter multivariable results of our primary outcome (advanced Gleason score). Information on place of birth was based on medical records. However, place of birth in the SEER data set has been shown to be accurate. 25 For example, a study of Asians from the Greater Bay area SEER cancer registry reported 99% of foreign born and 92% of US-born identified themselves as such in followup interviews. 25 An additional limitation of this study is that we were unable to determine the amount of time that immigrants in our study have been in the United States, which may impact dietary and other lifestyle factors contributing to disease severity. 26, 27 We were also unable to supplement this study with incidence data due to the lack of denominators available for foreign born blacks in SEER. While we were not able to measure the accuracy of Gleason score in this study, a previous study comparing SEER pathology records to urologic pathologists' reassessment of specimens reported moderate agreement. 28 Additionally, we were unable to account for potential variations in Gleason score based on biopsy versus radical prostatectomy 28 in our study, as the collaborative stage system during the time of our study did not differentiate between radical prostatectomy and biopsy scores. Radical prostatectomy rates varied by place of birth; 39.02, 31.84 and 23.76% of West African, Jamaican and US-born blacks underwent radical prostatectomy (P-value o0.01) and Gleason scores were higher among radical prostatectomy patients. Although we were unable to directly assess upgrading in our study, when radical prostatectomy was adjusted for, results were not altered. Furthermore, we used very broad Gleason score groups in our study (o7 versus X7 and o8 versus X8) and many studies report Gleason score discrepancies by one point increments. Agreement between radical prostatectomy and needle biopsy Gleason scores markedly improves when only differences of two or more points are considered. 9 Despite these limitations, we believe this descriptive study is the first to examine prostate cancer disease severity in African and Caribbean immigrants in the United States. We did not find differences in Gleason score and PSA between black men born in the United States and those born in Africa or the Caribbean. Future more detailed studies are needed to elucidate if these similarities are a result of similar early detection practices or shared risk factors.
